Results 11 to 20 of about 3,950 (204)

Phenotypic Characterization of Female Carrier Mice Heterozygous for Tafazzin Deletion

open access: yesBiology, 2023
Barth syndrome (BTHS) is caused by mutations in tafazzin resulting in deficits in cardiolipin remodeling that alter major metabolic processes. The tafazzin gene is encoded on the X chromosome, and therefore BTHS primarily affects males.
Michelle V. Tomczewski   +7 more
doaj   +4 more sources

Barth Syndrome: <i>TAFAZZIN</i> Gene, Cardiologic Aspects, and Mitochondrial Studies-A Comprehensive Narrative Review. [PDF]

open access: yesGenes (Basel)
Barth syndrome (BTHS) is inherited through an X-linked pattern. The gene is located on Xq28. Male individuals who inherit the TAFAZZIN pathogenic variant will have the associated condition, while female individuals who inherit the TAFAZZIN pathogenic ...
Sergi CM.
europepmc   +4 more sources

Cell-Penetrating Peptide Enhances Tafazzin Gene Therapy in Mouse Model of Barth Syndrome. [PDF]

open access: yesInt J Mol Sci
Barth Syndrome (BTHS) is an early onset, lethal X-linked disorder caused by a mutation in tafazzin (TAFAZZIN), a mitochondrial acyltransferase that remodels monolysocardiolipin (MLCL) to mature cardiolipin (CL) and is essential for normal mitochondrial ...
Raghav R   +5 more
europepmc   +4 more sources

Role of Tafazzin in Mitochondrial Function, Development and Disease [PDF]

open access: yesJournal of Developmental Biology, 2020
Tafazzin, an enzyme associated with the rare inherited x-linked disorder Barth Syndrome, is a nuclear encoded mitochondrial transacylase that is highly conserved across multiple species and plays an important role in mitochondrial function.
Michael T. Chin, Simon J. Conway
doaj   +3 more sources

Mouse tafazzin is required for male germ cell meiosis and spermatogenesis [PDF]

open access: yesPLOS ONE, 2015
Barth syndrome is an X-linked mitochondrial disease, symptoms of which include neutropenia and cardiac myopathy. These symptoms are the most significant clinical consequences of a disease, which is increasingly recognised to have a variable presentation.
Bryson, S.   +6 more
core   +20 more sources

Mitochondrial cardiolipin metabolism controlled by tafazzin enables ferroptosis

open access: yesbioRxiv
AbstractMitochondria are important producers of reactive oxygen species, which are involved in triggering ferroptosis, a lipid peroxidation driven form of cell death. Paradoxically, in the rare inherited metabolic disease Barth Syndrome, we discovered a protection from erastin-induced ferroptosis, despite intrinsically elevated mitochondrial ROS levels.
Wohlfarter Y   +17 more
europepmc   +3 more sources

Tafazzin modulates cellular phospholipid composition to regulate AML stemness [PDF]

open access: yesMolecular & Cellular Oncology, 2019
Tafazzin is a mitochondrial enzyme necessary for the remodeling of the phospholipid cardiolipin. Seneviratne and Xu et al. demonstrated that Tafazzin-mediated phospholipid production regulates stemness in Acute Myeloid Leukemia (AML). Tafazzin influenced
Ayesh K. Seneviratne   +2 more
doaj   +3 more sources

Stem cell models of TAFAZZIN deficiency reveal novel tissue-specific pathologies in Barth syndrome. [PDF]

open access: yesHum Mol Genet
Barth syndrome (BTHS) is a rare mitochondrial disease caused by pathogenic variants in the gene TAFAZZIN, which leads to abnormal cardiolipin (CL) metabolism on the inner mitochondrial membrane.
Sniezek Carney O   +8 more
europepmc   +3 more sources

Phenotypic Characterization of Male Tafazzin-Knockout Mice at 3, 6, and 12 Months of Age

open access: yesBiomedicines, 2023
Barth syndrome (BTHS) is an X-linked mitochondrial disease caused by mutations in the gene encoding for tafazzin (TAZ), a key enzyme in the remodeling of cardiolipin.
Michelle V. Tomczewski   +4 more
doaj   +2 more sources

Cranial, Renal, and Skeletal Anomalies in a Fetus With a Pathogenic Variant in the TAFAZZIN Gene. [PDF]

open access: yesPrenat Diagn
To report a case of a fetus with multiple congenital anomalies and suspected Barth syndrome, highlighting potential phenotypic expansion of the syndrome.
Muir CR, Gilmore KL, Singh S, Vora NL.
europepmc   +2 more sources

Home - About - Disclaimer - Privacy